NewAmsterdam Pharma Company announced the appointment of Juliette Audet as Chief Business Officer, CBO, and her simultaneous resignation from the Company’s Board of Directors, both effective April 1, 2024. Audet was most recently a Partner at Forbion, where she was part of the team that built NewAmsterdam Pharma, and played a key role in out licensing obicetrapib, setting up operations and recruiting the management team
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAMS:
- NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
- NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
- Scotiabank starts NewAmsterdam at Outperform on cholesteryl-lowering agent
- NewAmsterdam Pharma initiated with an Outperform at Scotiabank
- NewAmsterdam Pharma doses first patient in Phase 3 TANDEM trial
